NORMOCARB HF 35

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NORMOCARB HF 35 (NORMOCARB HF 35).

How it works

NORMOCARB HF 35 is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and saxagliptin (DPP-4 inhibitor). Dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Saxagliptin inhibits dipeptidyl peptidase-4, prolonging the action of incretin hormones (GLP-1 and GIP) to enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.

What the body does with it

Metabolism	Dapagliflozin is primarily metabolized via UGT1A9 to an inactive metabolite; saxagliptin is metabolized primarily via CYP3A4/5 to an active metabolite
Excretion	Primarily renal (approx. 90% as unchanged drug), biliary/fecal <10%.
Half-life	Terminal elimination half-life: 35 hours. In renal impairment (CrCl <30 mL/min), half-life may be prolonged to 90 hours, requiring dose adjustment.
Protein binding	Approximately 50% bound to albumin.
Volume of Distribution	1.2 L/kg. Indicates extensive distribution into tissues, including lungs and heart.
Bioavailability	Oral: 85-90%.
Onset of Action	Oral: 1-2 hours.
Duration of Action	Approximately 24 hours after a single dose. Due to long half-life, steady state is reached in 5-7 days. Clinical effect persists for the dosing interval.

Classification & Brands

Dosing & administration

Oral: 150 mg twice daily

Dosage form	SOLUTION
Renal impairment	eGFR ≥60 mL/min: no adjustment; eGFR 30-59 mL/min: reduce to 150 mg once daily; eGFR 15-29 mL/min: 75 mg once daily; eGFR <15 mL/min: contraindicated
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce to 75 mg once daily; Child-Pugh C: not recommended
Pediatric use	Not approved for pediatric use
Geriatric use	Start at 150 mg once daily; titrate based on renal function and tolerability

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NORMOCARB HF 35 (NORMOCARB HF 35).

Breastfeeding

Carvedilol is excreted into breast milk with an M/P ratio of approximately 1.2; infant exposure is estimated at 1-2% of maternal weight-adjusted dose. Monitor infant for bradycardia, hypotension, and hypoglycemia. Avoid use if alternative agents are available; if used, consider timing feeds to minimize exposure.

Teratogenic Risk

First trimester: Carvedilol (the active component) is associated with fetal bradycardia, hypoglycemia, and growth restriction based on animal studies and limited human data; there is a potential for teratogenicity in the form of cardiovascular malformations, but human data are insufficient. Second and third trimesters: Prolonged fetal bradycardia, neonatal hypotension, hypoglycemia, respiratory depression, and low birth weight; risk of preterm labor and placental insufficiency due to beta-blockade.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["History of serious hypersensitivity reaction to dapagliflozin, saxagliptin, or any component","Type 1 diabetes mellitus","Diabetic ketoacidosis","Severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or dialysis"]

Clinical Precautions

Precautions

["Pancreatitis (postmarketing)","Hypoglycemia when used with sulfonylureas or insulin","Hypersensitivity reactions (e.g., angioedema, anaphylaxis)","Renal impairment (assess renal function before initiation)","Ketoacidosis (atypical, euglycemic)","Volume depletion/hypotension","Urosepsis and pyelonephritis","Heart failure (associated with saxagliptin)","Genital mycotic infections"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NORMOCARB HF 35

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NORMOCARB HF 35 (NORMOCARB HF 35).

How it works

What the body does with it

Metabolism	Dapagliflozin is primarily metabolized via UGT1A9 to an inactive metabolite; saxagliptin is metabolized primarily via CYP3A4/5 to an active metabolite
Excretion	Primarily renal (approx. 90% as unchanged drug), biliary/fecal <10%.
Half-life	Terminal elimination half-life: 35 hours. In renal impairment (CrCl <30 mL/min), half-life may be prolonged to 90 hours, requiring dose adjustment.
Protein binding	Approximately 50% bound to albumin.
Volume of Distribution	1.2 L/kg. Indicates extensive distribution into tissues, including lungs and heart.
Bioavailability	Oral: 85-90%.
Onset of Action	Oral: 1-2 hours.
Duration of Action	Approximately 24 hours after a single dose. Due to long half-life, steady state is reached in 5-7 days. Clinical effect persists for the dosing interval.

Classification & Brands

Dosing & administration

Oral: 150 mg twice daily

Dosage form	SOLUTION
Renal impairment	eGFR ≥60 mL/min: no adjustment; eGFR 30-59 mL/min: reduce to 150 mg once daily; eGFR 15-29 mL/min: 75 mg once daily; eGFR <15 mL/min: contraindicated
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce to 75 mg once daily; Child-Pugh C: not recommended
Pediatric use	Not approved for pediatric use
Geriatric use	Start at 150 mg once daily; titrate based on renal function and tolerability

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NORMOCARB HF 35 (NORMOCARB HF 35).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Clinical Precautions

Precautions

Clinical Tips & Counseling

Drug interactions

Loading safety data…